ClinicalTrials.gov
ClinicalTrials.gov Menu

Bioavailability and Food Effect Study of Two Formulations of PF-06650833

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03308110
Recruitment Status : Completed
First Posted : October 12, 2017
Last Update Posted : April 18, 2018
Sponsor:
Information provided by (Responsible Party):
Pfizer

Brief Summary:
Bioavailability and food effect of 2 formulations of PF-06650833 in healthy volunteers.

Condition or disease Intervention/treatment Phase
Healthy Drug: PF-06650833 Phase 1

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 24 participants
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: A Phase 1, Single Dose, Open Label, Randomized, 5-period Crossover Study To Evaluate The Relative Bioavailability And Food Effect On New Modified Release Tablet Of Pf-06650833 In Healthy Subjects
Actual Study Start Date : September 12, 2017
Actual Primary Completion Date : December 8, 2017
Actual Study Completion Date : January 11, 2018

Arm Intervention/treatment
Relative Bioavailability Cohort
Relative Bioavailability cohort
Drug: PF-06650833
Two formulations of PF-006650833



Primary Outcome Measures :
  1. Cmax [ Time Frame: 0-96 hours ]
  2. AUClast [ Time Frame: 0-96 hours ]

Secondary Outcome Measures :
  1. Cmax under high fat meal fed conditions [ Time Frame: 0-96 hours ]
  2. Pharmacokinetic parameters of PF-06650833 from plasma concentration (if data permits) [ Time Frame: 0-96 hours ]
  3. AUClast under high fat meal fed conditions [ Time Frame: 0-96 hours ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy female subjects of nonchild bearing potential and/or male subjects who, at the time of screening, are between the ages of 18 and 55 years, inclusive.
  • Body mass index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lb).

Exclusion Criteria:

  • Subjects with any of the following characteristics/conditions will not be included in the study:

Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).

Any condition possibly affecting drug absorption (eg, gastrectomy).

  • A positive urine drug test.
  • History of regular alcohol consumption within 6 months before screening.
  • Treatment with an investigational drug within 30 days (or as determined by the local requirement) or 5 half lives preceding the first dose of investigational product (whichever is longer).
  • Screening supine BP greater than equal to 140 mm Hg (systolic) or more than equal to 90 mm Hg (diastolic), following at least 5 minutes of supine rest.
  • Pregnant female subjects; breastfeeding female subjects; female subjects of childbearing potential;
  • Use of prescription or nonprescription drugs and dietary supplements within 7 days or 5 half lives (whichever is longer) prior to the first dose of investigational product.
  • History of tuberculosis or active or latent or inadequately treated infection, positive QuantiFERON-TB Gold test.

History of human immunodeficiency virus (HIV), hepatitis B, or hepatitis C; positive testing for HIV, hepatitis B surface antigen (HepBsAg), hepatitis B core antibody (HepBcAb), or hepatitis C antibody (HCVAb).

-Other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03308110


Locations
Belgium
Pfizer Clinical Research Unit
Brussels, Belgium, B-1070
Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer

Additional Information:
Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT03308110     History of Changes
Other Study ID Numbers: B7921011
2017-002052-88 ( EudraCT Number )
First Posted: October 12, 2017    Key Record Dates
Last Update Posted: April 18, 2018
Last Verified: April 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No